IL6 and ovarian carcinoma: Through NF-κB, EGFR upregulates proinflammatory markers, IL-6 and plasminogen activation inhibitor (PAI-1), leading to increased proliferation in ovarian cancer cells.Co-expression of IL-6 and PAI-1 in epithelial ovarian cells was significantly associated with advanced-stage EOC and decreased survival [60].